+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Genitourinary Drugs Market by Product (Anti-infectives, Gynecological, Hormonal Therapy), Indication (Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer), Drug Type - Forecast 2024-2030- Product Image
Global Genitourinary Drugs Market by Product (Anti-infectives, Gynecological, Hormonal Therapy), Indication (Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer), Drug Type - Forecast 2024-2030- Product Image
Sale

Global Genitourinary Drugs Market by Product (Anti-infectives, Gynecological, Hormonal Therapy), Indication (Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer), Drug Type - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5454847
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Genitourinary Drugs Market size was estimated at USD 38.30 billion in 2023, USD 39.83 billion in 2024, and is expected to grow at a CAGR of 4.17% to reach USD 51.01 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Genitourinary Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Genitourinary Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Genitourinary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asieris Pharmaceuticals, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and The Bristol Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Genitourinary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Anti-infectives
    • Gynecological
    • Hormonal Therapy
    • Urologicals
  • Indication
    • Benign Prostatic Hyperplasia
    • Bladder Cancer
    • Cervical Cancer
    • Erectile Dysfunction
    • Hematuria
    • Interstitial Cystitis
    • Ovarian Cancer
    • Prostate Cancer
    • Renal Cancer
    • Sexually Transmitted Diseases
    • Urinary Incontinence & Overactive Bladder
    • Urinary Tract Infections
  • Drug Type
    • Hormonal Therapy
    • Impotence Agents
    • Urinary Antispasmodics
    • Urinary pH Modifiers
    • Uterine Relaxants
    • Uterine Stimulants
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Genitourinary Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Genitourinary Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Genitourinary Drugs Market?
  4. What is the market share of the leading vendors in the Genitourinary Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Genitourinary Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Genitourinary Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of genitourinary disorders
5.1.1.2. Rising number of pipeline drugs
5.1.1.3. Growing concerns about urinary incontinence and impotence
5.1.2. Restraints
5.1.2.1. Availability of counterfeit and generics drugs in the market
5.1.3. Opportunities
5.1.3.1. Collaborative R&D efforts by the pharma companies
5.1.3.2. Growing investment in healthcare for improved treatments
5.1.4. Challenges
5.1.4.1. Lack of compliance to medication
5.1.4.2. Continual patent expirations
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Genitourinary Drugs Market, by Product
6.1. Introduction
6.2. Anti-infectives
6.3. Gynecological
6.4. Hormonal Therapy
6.5. Urologicals
7. Genitourinary Drugs Market, by Indication
7.1. Introduction
7.2. Benign Prostatic Hyperplasia
7.3. Bladder Cancer
7.4. Cervical Cancer
7.5. Erectile Dysfunction
7.6. Hematuria
7.7. Interstitial Cystitis
7.8. Ovarian Cancer
7.9. Prostate Cancer
7.10. Renal Cancer
7.11. Sexually Transmitted Diseases
7.12. Urinary Incontinence & Overactive Bladder
7.13. Urinary Tract Infections
8. Genitourinary Drugs Market, by Drug Type
8.1. Introduction
8.2. Hormonal Therapy
8.3. Impotence Agents
8.4. Urinary Antispasmodics
8.5. Urinary pH Modifiers
8.6. Uterine Relaxants
8.7. Uterine Stimulants
9. Americas Genitourinary Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Genitourinary Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Genitourinary Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AbbVie Inc.
13.1.3. Asieris Pharmaceuticals
13.1.4. Astellas Pharma Inc.
13.1.5. AstraZeneca PLC
13.1.6. Bayer AG
13.1.7. Cipla Inc.
13.1.8. Eli Lilly and Company
13.1.9. F. Hoffmann-La Roche Ltd.
13.1.10. GlaxoSmithKline PLC
13.1.11. Johnson & Johnson Services, Inc.
13.1.12. Merck & Co., Inc.
13.1.13. Novartis AG
13.1.14. Pfizer, Inc.
13.1.15. Teva Pharmaceutical Industries Ltd.
13.1.16. The Bristol Myers Squibb Company
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GENITOURINARY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GENITOURINARY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GENITOURINARY DRUGS MARKET DYNAMICS
FIGURE 7. GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 12. GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. GENITOURINARY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. GENITOURINARY DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. GENITOURINARY DRUGS MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GENITOURINARY DRUGS MARKET SIZE, BY UROLOGICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 11. GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GENITOURINARY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GENITOURINARY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GENITOURINARY DRUGS MARKET SIZE, BY HEMATURIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GENITOURINARY DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GENITOURINARY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GENITOURINARY DRUGS MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GENITOURINARY DRUGS MARKET SIZE, BY URINARY INCONTINENCE & OVERACTIVE BLADDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 24. GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GENITOURINARY DRUGS MARKET SIZE, BY IMPOTENCE AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GENITOURINARY DRUGS MARKET SIZE, BY URINARY ANTISPASMODICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GENITOURINARY DRUGS MARKET SIZE, BY URINARY PH MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GENITOURINARY DRUGS MARKET SIZE, BY UTERINE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GENITOURINARY DRUGS MARKET SIZE, BY UTERINE STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. CANADA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. CANADA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 44. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. CHINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. CHINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. CHINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. INDIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 61. INDIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. INDIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 73. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 79. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 85. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 107. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 110. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. ITALY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 113. ITALY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. ITALY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 122. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. POLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. POLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. POLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. QATAR GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 128. QATAR GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. QATAR GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 146. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 158. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 159. GENITOURINARY DRUGS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Asieris Pharmaceuticals
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cipla Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol Myers Squibb Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 39.83 Billion
Forecasted Market Value ( USD ) by 2030 $ 51.01 Billion
Compound Annual Growth Rate4.1%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Genitourinary Drugs Market Size, Share & Trends Analysis Report By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), By Product (Hormonal Therapy, Gynecological), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Genitourinary Drugs Market Size, Share & Trends Analysis Report By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), By Product (Hormonal Therapy, Gynecological), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 110 Pages
  • Global
From
Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 181 Pages
  • Global
From
Genitourinary Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Genitourinary Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 144 Pages
  • Global
From
Global Genitourinary Drugs Market Report and Forecast 2023-2031 - Product Image

Global Genitourinary Drugs Market Report and Forecast 2023-2031

  • Report
  • 147 Pages
  • Global
From
Genitourinary Drugs: Global Strategic Business Report - Product Image

Genitourinary Drugs: Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Genitourinary Drug Market

The Genitourinary Drug market is a subset of the pharmaceutical industry that focuses on drugs used to treat urological disorders. These drugs are used to treat a variety of conditions, including urinary tract infections, bladder control issues, kidney stones, and prostate enlargement. Genitourinary drugs are also used to treat erectile dysfunction, infertility, and other sexual health issues. These drugs are typically prescribed by urologists and other healthcare professionals. The Genitourinary Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, AstraZeneca, Sanofi, and Bayer. Other companies in the market include Allergan, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.